UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000028166
Receipt No. R000031670
Scientific Title Phase II study of osimertinib in patients with non-small cell lung cancer who acquired resistance to afatinib
Date of disclosure of the study information 2017/08/01
Last modified on 2017/07/10

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Phase II study of osimertinib in patients with non-small cell lung cancer who acquired resistance to afatinib
Acronym Phase II study of osimertinib in patients with non-small cell lung cancer who acquired resistance to afatinib (ALCSG-04)
Scientific Title Phase II study of osimertinib in patients with non-small cell lung cancer who acquired resistance to afatinib
Scientific Title:Acronym Phase II study of osimertinib in patients with non-small cell lung cancer who acquired resistance to afatinib (ALCSG-04)
Region
Japan

Condition
Condition Non-small cell lung cancer
Classification by specialty
Pneumology
Classification by malignancy Malignancy
Genomic information YES

Objectives
Narrative objectives1 To evaluate the efficacy of osimertinib in patients harboring EGFR T790M mutation who acquired resistance to afatinib as first line.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Response rate
Key secondary outcomes

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
75 years-old >
Gender Male and Female
Key inclusion criteria Eligibility includes;
1. Patients of lung cancer diagnosed with pathological findings and clinical stage from IIIA to IV.
2. Patients harboring active EGFR gene mutations.
3. Patients having one or more measurable lesions based on RECIST v1.1.
4. Patients aged 20 and over 20, and less than 75 years.
5. Patients who are not treated with chemotherapy, EGFR-TKIs, and Immuno-checkpoint blockades.
6. Patients who can take EGFR-TKIs orally.
7. Patients having adequate organ function.
8. Letter of consent.
Key exclusion criteria Patients are excluded if they have;
1. Severe concomitant disease.
2. Severe history oh hypersensitivity.
3. Severe heart disease or arrhythmia.
4. Interstitial pneumoniae.
5. Active infection.
6. Active peptic ulcer.
7. Active double cancer.
8. Symptomatic brain metastasis.
Target sample size 50

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Takaaki Sasaki
Organization Asahikawa Medical University Hospital
Division name Respiratory Center
Zip code
Address 2-1-1-1 Midorigaoka-higashi, Asahikawa-shi, Hokkaido, 078-8510 Japan
TEL 0166-65-2111
Email yryohei@asahikawa-med.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Kaori Onishi
Organization Asahikawa Medical University Hospital
Division name Respiratory Center
Zip code
Address 2-1-1-1 Midorigaoka-higashi, Asahikawa-shi, Hokkaido, 078-8510 Japan
TEL 0166-65-2111
Homepage URL
Email k-onishi@asahikawa-med.ac.jp

Sponsor
Institute Asahikawa Medical University Hospital
Institute
Department

Funding Source
Organization Asahikawa Medical University Hospital, Respiratory center
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor Asahikawa Lung Cancer Study Group(ALCSG)
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2017 Year 08 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2017 Year 07 Month 01 Day
Date of IRB
Anticipated trial start date
2017 Year 08 Month 01 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information No mention.

Management information
Registered date
2017 Year 07 Month 10 Day
Last modified on
2017 Year 07 Month 10 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000031670

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.